Report from the SWOG radiation oncology committee: Research objectives workshop 2017

Paul Okunieff, Katherine Casey-Sawicki, Natalie A. Lockney, Bradford S. Hoppe, Heiko Enderling, Chelsea Pinnix, James Welsh, Sunil Krishnan, Greg Yothers, Martin Brown, Susan Knox, Robert Bristow, Paul Spellman, Timur Mitin, Nima Nabavizadeh, Jerry Jaboin, H. Charles Manning, Felix Feng, Susan Galbraith, Abhishek A. SolankiMatthew M. Harkenrider, Richard Tuli, Roy H. Decker, Steven E. Finkelstein, Charles C. Hsu, Chul S. Ha, Reshma Jagsi, Dean Shumway, Megan Daly, Tony J.C. Wang, Thomas J. Fitzgerald, Fran Laurie, David T. Marshall, David Raben, Louis Constine, Charles Thomas, Lisa A. Kachnic

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Radiation Therapy Committee of SWOG periodically evaluates its strategic plan in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2017 Strategic Planning Workshop included leaders in cancer basic sciences, molecular theragnostics, pharmaceutical and technology industries, clinical trial design, oncology practice, and statistical analysis. The committee discussed high-priority research areas, such as optimization of combined modality therapy, radiation oncology-specific drug design, identification of molecular profiles predictive of radiation-induced local or distant tumor responses, and methods for normal tissue-specific mitigation of radiation toxicity. The following concepts emerged as dominant questions ready for national testing: (i) what is the role of radiotherapy in the treatment of oligometastatic, oligorecurrent, and oligoprogressive disease? (ii) How can combined modality therapy be used to enhance systemic and local response? (iii) Can we validate and optimize liquid biopsy and other biomarkers (such as novel imaging) to supplement current response criteria to guide therapy and clinical trial design endpoints? (iv) How can we overcome deficiencies of randomized survival endpoint trials in an era of increasing molecular stratification factors? And (v) how can we mitigate treatment-related side effects and maximize quality of life in cancer survivors? The committee concluded that many aspects of these questions are ready for clinical evaluation and example protocol concepts are provided that could improve rates of cancer cure and quality of survival. 2018 American Association for Cancer Research.

Original languageEnglish (US)
Pages (from-to)3500-3509
Number of pages10
JournalClinical Cancer Research
Volume24
Issue number15
DOIs
StatePublished - Aug 1 2018

Fingerprint

Radiation Oncology
Education
Combined Modality Therapy
Research
Neoplasms
Radiotherapy
Pharmaceutical Technology
Clinical Trials
Radiation
Survival
Drug Design
Drug Industry
Survivors
Therapeutics
Biomarkers
Quality of Life
Biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. S., Enderling, H., Pinnix, C., ... Kachnic, L. A. (2018). Report from the SWOG radiation oncology committee: Research objectives workshop 2017. Clinical Cancer Research, 24(15), 3500-3509. https://doi.org/10.1158/1078-0432.CCR-17-3202

Report from the SWOG radiation oncology committee : Research objectives workshop 2017. / Okunieff, Paul; Casey-Sawicki, Katherine; Lockney, Natalie A.; Hoppe, Bradford S.; Enderling, Heiko; Pinnix, Chelsea; Welsh, James; Krishnan, Sunil; Yothers, Greg; Brown, Martin; Knox, Susan; Bristow, Robert; Spellman, Paul; Mitin, Timur; Nabavizadeh, Nima; Jaboin, Jerry; Manning, H. Charles; Feng, Felix; Galbraith, Susan; Solanki, Abhishek A.; Harkenrider, Matthew M.; Tuli, Richard; Decker, Roy H.; Finkelstein, Steven E.; Hsu, Charles C.; Ha, Chul S.; Jagsi, Reshma; Shumway, Dean; Daly, Megan; Wang, Tony J.C.; Fitzgerald, Thomas J.; Laurie, Fran; Marshall, David T.; Raben, David; Constine, Louis; Thomas, Charles; Kachnic, Lisa A.

In: Clinical Cancer Research, Vol. 24, No. 15, 01.08.2018, p. 3500-3509.

Research output: Contribution to journalArticle

Okunieff, P, Casey-Sawicki, K, Lockney, NA, Hoppe, BS, Enderling, H, Pinnix, C, Welsh, J, Krishnan, S, Yothers, G, Brown, M, Knox, S, Bristow, R, Spellman, P, Mitin, T, Nabavizadeh, N, Jaboin, J, Manning, HC, Feng, F, Galbraith, S, Solanki, AA, Harkenrider, MM, Tuli, R, Decker, RH, Finkelstein, SE, Hsu, CC, Ha, CS, Jagsi, R, Shumway, D, Daly, M, Wang, TJC, Fitzgerald, TJ, Laurie, F, Marshall, DT, Raben, D, Constine, L, Thomas, C & Kachnic, LA 2018, 'Report from the SWOG radiation oncology committee: Research objectives workshop 2017', Clinical Cancer Research, vol. 24, no. 15, pp. 3500-3509. https://doi.org/10.1158/1078-0432.CCR-17-3202
Okunieff P, Casey-Sawicki K, Lockney NA, Hoppe BS, Enderling H, Pinnix C et al. Report from the SWOG radiation oncology committee: Research objectives workshop 2017. Clinical Cancer Research. 2018 Aug 1;24(15):3500-3509. https://doi.org/10.1158/1078-0432.CCR-17-3202
Okunieff, Paul ; Casey-Sawicki, Katherine ; Lockney, Natalie A. ; Hoppe, Bradford S. ; Enderling, Heiko ; Pinnix, Chelsea ; Welsh, James ; Krishnan, Sunil ; Yothers, Greg ; Brown, Martin ; Knox, Susan ; Bristow, Robert ; Spellman, Paul ; Mitin, Timur ; Nabavizadeh, Nima ; Jaboin, Jerry ; Manning, H. Charles ; Feng, Felix ; Galbraith, Susan ; Solanki, Abhishek A. ; Harkenrider, Matthew M. ; Tuli, Richard ; Decker, Roy H. ; Finkelstein, Steven E. ; Hsu, Charles C. ; Ha, Chul S. ; Jagsi, Reshma ; Shumway, Dean ; Daly, Megan ; Wang, Tony J.C. ; Fitzgerald, Thomas J. ; Laurie, Fran ; Marshall, David T. ; Raben, David ; Constine, Louis ; Thomas, Charles ; Kachnic, Lisa A. / Report from the SWOG radiation oncology committee : Research objectives workshop 2017. In: Clinical Cancer Research. 2018 ; Vol. 24, No. 15. pp. 3500-3509.
@article{7420127fa6f54effbdf1f0e5a4dfb84a,
title = "Report from the SWOG radiation oncology committee: Research objectives workshop 2017",
abstract = "The Radiation Therapy Committee of SWOG periodically evaluates its strategic plan in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2017 Strategic Planning Workshop included leaders in cancer basic sciences, molecular theragnostics, pharmaceutical and technology industries, clinical trial design, oncology practice, and statistical analysis. The committee discussed high-priority research areas, such as optimization of combined modality therapy, radiation oncology-specific drug design, identification of molecular profiles predictive of radiation-induced local or distant tumor responses, and methods for normal tissue-specific mitigation of radiation toxicity. The following concepts emerged as dominant questions ready for national testing: (i) what is the role of radiotherapy in the treatment of oligometastatic, oligorecurrent, and oligoprogressive disease? (ii) How can combined modality therapy be used to enhance systemic and local response? (iii) Can we validate and optimize liquid biopsy and other biomarkers (such as novel imaging) to supplement current response criteria to guide therapy and clinical trial design endpoints? (iv) How can we overcome deficiencies of randomized survival endpoint trials in an era of increasing molecular stratification factors? And (v) how can we mitigate treatment-related side effects and maximize quality of life in cancer survivors? The committee concluded that many aspects of these questions are ready for clinical evaluation and example protocol concepts are provided that could improve rates of cancer cure and quality of survival. 2018 American Association for Cancer Research.",
author = "Paul Okunieff and Katherine Casey-Sawicki and Lockney, {Natalie A.} and Hoppe, {Bradford S.} and Heiko Enderling and Chelsea Pinnix and James Welsh and Sunil Krishnan and Greg Yothers and Martin Brown and Susan Knox and Robert Bristow and Paul Spellman and Timur Mitin and Nima Nabavizadeh and Jerry Jaboin and Manning, {H. Charles} and Felix Feng and Susan Galbraith and Solanki, {Abhishek A.} and Harkenrider, {Matthew M.} and Richard Tuli and Decker, {Roy H.} and Finkelstein, {Steven E.} and Hsu, {Charles C.} and Ha, {Chul S.} and Reshma Jagsi and Dean Shumway and Megan Daly and Wang, {Tony J.C.} and Fitzgerald, {Thomas J.} and Fran Laurie and Marshall, {David T.} and David Raben and Louis Constine and Charles Thomas and Kachnic, {Lisa A.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1158/1078-0432.CCR-17-3202",
language = "English (US)",
volume = "24",
pages = "3500--3509",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Report from the SWOG radiation oncology committee

T2 - Research objectives workshop 2017

AU - Okunieff, Paul

AU - Casey-Sawicki, Katherine

AU - Lockney, Natalie A.

AU - Hoppe, Bradford S.

AU - Enderling, Heiko

AU - Pinnix, Chelsea

AU - Welsh, James

AU - Krishnan, Sunil

AU - Yothers, Greg

AU - Brown, Martin

AU - Knox, Susan

AU - Bristow, Robert

AU - Spellman, Paul

AU - Mitin, Timur

AU - Nabavizadeh, Nima

AU - Jaboin, Jerry

AU - Manning, H. Charles

AU - Feng, Felix

AU - Galbraith, Susan

AU - Solanki, Abhishek A.

AU - Harkenrider, Matthew M.

AU - Tuli, Richard

AU - Decker, Roy H.

AU - Finkelstein, Steven E.

AU - Hsu, Charles C.

AU - Ha, Chul S.

AU - Jagsi, Reshma

AU - Shumway, Dean

AU - Daly, Megan

AU - Wang, Tony J.C.

AU - Fitzgerald, Thomas J.

AU - Laurie, Fran

AU - Marshall, David T.

AU - Raben, David

AU - Constine, Louis

AU - Thomas, Charles

AU - Kachnic, Lisa A.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - The Radiation Therapy Committee of SWOG periodically evaluates its strategic plan in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2017 Strategic Planning Workshop included leaders in cancer basic sciences, molecular theragnostics, pharmaceutical and technology industries, clinical trial design, oncology practice, and statistical analysis. The committee discussed high-priority research areas, such as optimization of combined modality therapy, radiation oncology-specific drug design, identification of molecular profiles predictive of radiation-induced local or distant tumor responses, and methods for normal tissue-specific mitigation of radiation toxicity. The following concepts emerged as dominant questions ready for national testing: (i) what is the role of radiotherapy in the treatment of oligometastatic, oligorecurrent, and oligoprogressive disease? (ii) How can combined modality therapy be used to enhance systemic and local response? (iii) Can we validate and optimize liquid biopsy and other biomarkers (such as novel imaging) to supplement current response criteria to guide therapy and clinical trial design endpoints? (iv) How can we overcome deficiencies of randomized survival endpoint trials in an era of increasing molecular stratification factors? And (v) how can we mitigate treatment-related side effects and maximize quality of life in cancer survivors? The committee concluded that many aspects of these questions are ready for clinical evaluation and example protocol concepts are provided that could improve rates of cancer cure and quality of survival. 2018 American Association for Cancer Research.

AB - The Radiation Therapy Committee of SWOG periodically evaluates its strategic plan in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2017 Strategic Planning Workshop included leaders in cancer basic sciences, molecular theragnostics, pharmaceutical and technology industries, clinical trial design, oncology practice, and statistical analysis. The committee discussed high-priority research areas, such as optimization of combined modality therapy, radiation oncology-specific drug design, identification of molecular profiles predictive of radiation-induced local or distant tumor responses, and methods for normal tissue-specific mitigation of radiation toxicity. The following concepts emerged as dominant questions ready for national testing: (i) what is the role of radiotherapy in the treatment of oligometastatic, oligorecurrent, and oligoprogressive disease? (ii) How can combined modality therapy be used to enhance systemic and local response? (iii) Can we validate and optimize liquid biopsy and other biomarkers (such as novel imaging) to supplement current response criteria to guide therapy and clinical trial design endpoints? (iv) How can we overcome deficiencies of randomized survival endpoint trials in an era of increasing molecular stratification factors? And (v) how can we mitigate treatment-related side effects and maximize quality of life in cancer survivors? The committee concluded that many aspects of these questions are ready for clinical evaluation and example protocol concepts are provided that could improve rates of cancer cure and quality of survival. 2018 American Association for Cancer Research.

UR - http://www.scopus.com/inward/record.url?scp=85051118714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051118714&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-3202

DO - 10.1158/1078-0432.CCR-17-3202

M3 - Article

C2 - 29661779

AN - SCOPUS:85051118714

VL - 24

SP - 3500

EP - 3509

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -